Biomarker Panel for the Diagnosis of Pancreatic Ductal Adenocarcinoma
A single tumor marker has a low diagnostic value in pancreatic cancer. Combinations of multiple biomarkers and unique analysis algorithms can be applied to overcome these limitations. This study sought to develop diagnostic algorithms using multiple biomarker panels and to validate their performance...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-06-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/12/6/1443 |
| _version_ | 1797566386311004160 |
|---|---|
| author | Hongbeom Kim Kyung Nam Kang Yong Sung Shin Yoonhyeong Byun Youngmin Han Wooil Kwon Chul Woo Kim Jin-Young Jang |
| author_facet | Hongbeom Kim Kyung Nam Kang Yong Sung Shin Yoonhyeong Byun Youngmin Han Wooil Kwon Chul Woo Kim Jin-Young Jang |
| author_sort | Hongbeom Kim |
| collection | DOAJ |
| description | A single tumor marker has a low diagnostic value in pancreatic cancer. Combinations of multiple biomarkers and unique analysis algorithms can be applied to overcome these limitations. This study sought to develop diagnostic algorithms using multiple biomarker panels and to validate their performance in the diagnosis of pancreatic ductal adenocarcinoma (PDAC). We used blood samples from 180 PDAC patients and 573 healthy controls. Candidate markers consisted of 11 markers that are commonly expressed in various cancers and which have previously demonstrated increased expression in pancreatic cancer. Samples were divided into training and validation sets. Five linear or non-linear classification methods were used to determine the optimal model. Differences were identified in 10 out of the 11 markers tested. We identified 2047 combinations, all of which were applied to 5 separate algorithms. The new biomarker combination consisted of 6 markers (ApoA1, CA125, CA19-9, CEA, ApoA2, and TTR). The area under the curve, specificity, and sensitivity were 0.992, 95%, and 96%, respectively, in the training set. Meanwhile, the measures were 0.993, 96%, and 93% in the validation set. This study demonstrated the utility of multiple biomarker combinations in the early detection of PDAC. A diagnostic panel of 6 biomarkers was developed and validated. These algorithms will assist in the early diagnosis of PDAC. |
| first_indexed | 2024-03-10T19:27:02Z |
| format | Article |
| id | doaj.art-b14bc00fc97a40e0bae44d37a74f1e0f |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T19:27:02Z |
| publishDate | 2020-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-b14bc00fc97a40e0bae44d37a74f1e0f2023-11-20T02:31:08ZengMDPI AGCancers2072-66942020-06-01126144310.3390/cancers12061443Biomarker Panel for the Diagnosis of Pancreatic Ductal AdenocarcinomaHongbeom Kim0Kyung Nam Kang1Yong Sung Shin2Yoonhyeong Byun3Youngmin Han4Wooil Kwon5Chul Woo Kim6Jin-Young Jang7Departments of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul 03080, KoreaBIOINFRA Life Science Inc., Seoul 03127, KoreaBIOINFRA Life Science Inc., Seoul 03127, KoreaDepartments of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul 03080, KoreaDepartments of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul 03080, KoreaDepartments of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul 03080, KoreaBIOINFRA Life Science Inc., Seoul 03127, KoreaDepartments of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul 03080, KoreaA single tumor marker has a low diagnostic value in pancreatic cancer. Combinations of multiple biomarkers and unique analysis algorithms can be applied to overcome these limitations. This study sought to develop diagnostic algorithms using multiple biomarker panels and to validate their performance in the diagnosis of pancreatic ductal adenocarcinoma (PDAC). We used blood samples from 180 PDAC patients and 573 healthy controls. Candidate markers consisted of 11 markers that are commonly expressed in various cancers and which have previously demonstrated increased expression in pancreatic cancer. Samples were divided into training and validation sets. Five linear or non-linear classification methods were used to determine the optimal model. Differences were identified in 10 out of the 11 markers tested. We identified 2047 combinations, all of which were applied to 5 separate algorithms. The new biomarker combination consisted of 6 markers (ApoA1, CA125, CA19-9, CEA, ApoA2, and TTR). The area under the curve, specificity, and sensitivity were 0.992, 95%, and 96%, respectively, in the training set. Meanwhile, the measures were 0.993, 96%, and 93% in the validation set. This study demonstrated the utility of multiple biomarker combinations in the early detection of PDAC. A diagnostic panel of 6 biomarkers was developed and validated. These algorithms will assist in the early diagnosis of PDAC.https://www.mdpi.com/2072-6694/12/6/1443pancreascancerscreeningdiagnosisbiomarker |
| spellingShingle | Hongbeom Kim Kyung Nam Kang Yong Sung Shin Yoonhyeong Byun Youngmin Han Wooil Kwon Chul Woo Kim Jin-Young Jang Biomarker Panel for the Diagnosis of Pancreatic Ductal Adenocarcinoma Cancers pancreas cancer screening diagnosis biomarker |
| title | Biomarker Panel for the Diagnosis of Pancreatic Ductal Adenocarcinoma |
| title_full | Biomarker Panel for the Diagnosis of Pancreatic Ductal Adenocarcinoma |
| title_fullStr | Biomarker Panel for the Diagnosis of Pancreatic Ductal Adenocarcinoma |
| title_full_unstemmed | Biomarker Panel for the Diagnosis of Pancreatic Ductal Adenocarcinoma |
| title_short | Biomarker Panel for the Diagnosis of Pancreatic Ductal Adenocarcinoma |
| title_sort | biomarker panel for the diagnosis of pancreatic ductal adenocarcinoma |
| topic | pancreas cancer screening diagnosis biomarker |
| url | https://www.mdpi.com/2072-6694/12/6/1443 |
| work_keys_str_mv | AT hongbeomkim biomarkerpanelforthediagnosisofpancreaticductaladenocarcinoma AT kyungnamkang biomarkerpanelforthediagnosisofpancreaticductaladenocarcinoma AT yongsungshin biomarkerpanelforthediagnosisofpancreaticductaladenocarcinoma AT yoonhyeongbyun biomarkerpanelforthediagnosisofpancreaticductaladenocarcinoma AT youngminhan biomarkerpanelforthediagnosisofpancreaticductaladenocarcinoma AT wooilkwon biomarkerpanelforthediagnosisofpancreaticductaladenocarcinoma AT chulwookim biomarkerpanelforthediagnosisofpancreaticductaladenocarcinoma AT jinyoungjang biomarkerpanelforthediagnosisofpancreaticductaladenocarcinoma |